{"denoms":[{"counts":[{"groupId":"BG000","value":"200"},{"groupId":"BG001","value":"200"},{"groupId":"BG002","value":"400"}],"units":"Participants"}],"groups":[{"description":"Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"BG000","title":"Atezolizumab Plus Bevacizumab Plus Chemotherapy"},{"description":"Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"BG001","title":"Bevacizumab Plus Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"42.3","upperLimit":"87.6","value":"70.7"},{"groupId":"BG001","lowerLimit":"47.7","upperLimit":"88.2","value":"70.1"},{"groupId":"BG002","lowerLimit":"42.3","upperLimit":"88.2","value":"70.4"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"84"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"160"},{"groupId":"BG001","value":"156"},{"groupId":"BG002","value":"316"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"199"},{"groupId":"BG001","value":"200"},{"groupId":"BG002","value":"399"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Black"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"26"}],"title":"Current smoker"},{"measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"198"}],"title":"Former smoker"},{"measurements":[{"groupId":"BG000","value":"86"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"176"}],"title":"Never smoked"}]}],"description":"Current smoker: Still smokes cigarettes, Former smoker: Smoked at least 100 cigarettes in the past during the whole life, Never smoker: Smoked 0-99 cigarettes during the whole life.","paramType":"COUNT_OF_PARTICIPANTS","title":"Smoking status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"141"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"119"},{"groupId":"BG001","value":"139"},{"groupId":"BG002","value":"258"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Unknown/Missing"}]}],"description":"0: Fully active, able to carry on all pre-disease performance without restriction; 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"84"}],"title":"IV"},{"measurements":[{"groupId":"BG000","value":"157"},{"groupId":"BG001","value":"159"},{"groupId":"BG002","value":"316"}],"title":"Other"}]}],"description":"Stage is based on the 8th TNM classification for Malignant Pleural Mesothelioma (American Joint Committee on Cancer) and is categorized here as \"IV\" (advanced stage) vs \"Other\" including the following stage categories: I (IA or IB), II, III (IIIA or IIIB).","paramType":"COUNT_OF_PARTICIPANTS","title":"Stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"157"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"311"}],"title":"Epithelioid"},{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"89"}],"title":"Non pure epithelioid"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"89"},{"groupId":"BG002","value":"173"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"109"}],"title":"Possible"},{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"81"}],"title":"No"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"37"}],"title":"Unknown/Missing"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Asbestos exposure","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"117"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"215"}],"title":"<1"},{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"122"}],"title":"1-49"},{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"47"}],"title":"≥50"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"16"}],"title":"Unknown/Missing"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"PD-L1 TPS%","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"146"},{"groupId":"BG001","value":"134"},{"groupId":"BG002","value":"280"}],"title":"Good prognosis"},{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"120"}],"title":"Poor prognosis"}]}],"description":"EORTC PROGNOSTIC SCORE: Curran et al. Journal of Clinical Oncology. 1998 Jan; Vol16:145-152","paramType":"COUNT_OF_PARTICIPANTS","title":"EORTC prognostic score","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"136"}],"title":"0-Favorable"},{"measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"129"}],"title":"1-Intermediate"},{"measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"135"}],"title":"2-Poor"}]}],"description":"Mesothelioma risk score (MRS): Banna et al. Lung Cancer. 2022 Jul; 169:77-83 The risk factors are baseline systemic immune-inflammatory index (good: \\< 1,250 vs poor: ≥ 1,250) and baseline haemoglobin (good: ≥ LLN vs poor: \\< LLN) (LLN = 135 for males, LLN = 120 for females))","paramType":"COUNT_OF_PARTICIPANTS","title":"Mesothelioma risk score (MRS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"189"},{"groupId":"BG001","value":"187"},{"groupId":"BG002","value":"376"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"24"}],"title":"No"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Medical history","unitOfMeasure":"Participants"}]}